SKSatoshi Kiyama

Satoshi Kiyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Satoshi Kiyama has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma

    by Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Masaru Yamashita

    Objectives: The purpose of this study is to investigate the genetic mutational status of recurrent/metastatic papillary thyroid carcinoma (PTC) and its prognostic implications. Methods: Data were analyzed for 348 consecutive patients with PTC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and February 2026. Genetic mutations were determined by next generation sequencing. Survival of patients was determined by log‐rank test and a Cox proportional hazards model. Results: The top 10 mutations in recurrent/metastatic PTC were TERT (82.2%), BRAF (78.7%), LTK (16.1%), CDKN2A (15.2%), KMT2D (14.4%), NOTCH3 (14.1%), TP53 (12.9%), PIK3CA (11.5%), CDKN2B (10.6%), STK11 (10.3%), with 11.0 ± 0.19 (mean ± SEM) mutations/individual. BRAF ( p = 0.0379), CDKN2A ( p = 7.41 × 10 −12 ), KMT2D ( p = 0.0048), PIK3CA ( p = 0.0406), CDKN2B ( p = 7.24 × 10 −13 ), and concurrent TERT/BRAF ( p = 0.0141) were associated with a significantly worse prognosis, as determined by log‐rank test. Multivariable Cox proportional hazards analysis was 3.762 (95% CI, 1.7480–8.095; p = 7.026 × 10 −4 ) for CDKN2A , 2.620 (1.50–4.575; p = 7.076 × 10 −4 ) for KMT2D, 1.882 (1.127–3.143; p = 0.01572) for concurrent TERT/BRAF . Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic PTC and identified several alterations with significant prognostic relevance. Even in advanced disease, specific mutations such as CDKN2A , KMT2D , and concurrent TERT/BRAF remained strongly associated with poor survival, underscoring the clinical value of comprehensive cancer genomic profiling in this population. Level of Evidence: 3.

  • Genetic mutations in neuroendocrine carcinomas of unknown primary

    by Hiromi Nagano, Satoshi Kiyama, Kyutoku Takayuki, Masaru Yamashita

    Introduction: Although genetic mutations have been reported in neuroendocrine carcinomas of unknown primary (NECs-UP), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of NECs-UP and its potential therapeutic relevance.Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic NEC-UP.Materials and methods: Data were analyzed for 122 consecutive patients with NECs-UP registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and August 2025. Genetic mutations were determined by next-generation sequencing. Survival of patients was determined by log-rank test and a Cox proportional hazards model.Results: The top 10 mutations in NECs-UP were TP53 (71.3%), RB1 (49.2%), KMT2D (24.6%), NOTCH1 (20.5%), CDKN2A (18.0%), SPEN (15.6%), ARID1A (15.6%), RICTOR (15.6%), CIC (14.8%), SDHA (14.8%), with 16.3 7.1 (mean SD) mutations/individual. Mutation in TP53 (p = 0.0474) and CIC (p = 0.0322) were associated with a significantly worse prognosis, as determined by log-rank test. The hazard ratios for cases with this mutation was 2.0550 (95% CI, 1.0540-4.006, p = 0.03455) for CIC.Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic NECs-UP. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.


  • Genetic mutations in metastatic adenocarcinoma of unknown primary

    by Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Hayato Matsumoto, Masaru Yamashita

    Introduction: Although several genomic alterations have been reported in adenocarcinoma of unknown primary (ACUP), molecularly targeted therapies are not yet clinically established, and comprehensive genomic profiling (CGP) is rarely used in daily practice.Aim: To charaterize the molecular landscape and prognostic impact of key mutations in recurrent or metastatic ACUP.Materials and methods: Data from 480 consecutive ACUP patients registered in Japan’s National Cancer Center (C-CAT) between June 2019 and August 2025 were analyzed. Somatic mutations were identified using the FoundationOne CDx platform. Overall survival (OS) was assessed by Kaplan–Meier analysis, log-rank tests, and multivariate Cox proportional hazards modeling.Results: The most frequent alterations were TP53 (59.4%), KRAS (31.5%), CDKN2A (26.3%), KMT2D (22.3%), LTK (17.9%), NOTCH3 (16.9%), STK11 (16.3%), CDKN2B (15.8%), ERBB2 (15.4%), and GNAS (15.2%). Patients harbored a mean of 17.3 9.9 mutations per patient (mean SD). Mutations in GNAS (p = 0.046) and PIK3CA (p = 0.025) were associated with better OS, whereas ARID1A (p = 0.049) and NOTCH1 (p = 0.038) predicted worse OS. In Cox analysis, hazard ratios (HR [95% CI]) were 0.57 (0.36–0.92, p = 0.020) for GNAS, 0.57 (0.33–0.96, p = 0.033) for PIK3CA, 1.98 (1.27–3.09, p = 0.0024) for ARID1A, and 1.84 (1.17–2.91, p = 0.0090) for NOTCH1.Conclusions: GNAS and PIK3CA mutations were linked to favorable outcomes, while ARID1A and NOTCH1 alterations indicated poor prognosis in ACUP. These results highlight the prognostic significance of specific genomic alterations and support integrating CGP into the clinical management of ACUP.

  • Genetic mutations in salivary duct carcinoma

    by Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Hayato Matsumoto, Masaru Yamashita

    Introduction: Although genetic mutations have been reported in salivary duct carcinoma (SDC), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of SDC and its potential therapeutic relevance. Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic SDC. Materials and methods: Data were analyzed for 207 consecutive patients with SDC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and October 2025. Genetic mutations were determined by next-generation sequencing. Survival of patients was determined by the log-rank test and the Cox proportional hazards model. Results: The top 10 mutations in SDC were TP53 (74.4%), ERBB2 (52.2%), NF1 (32.4%), CDK12 (29.0%), PIK3CA (28.0%), NOTCH3 (19.8%), LTK (18.4%), CDKN2A (18.4%), BRCA2 (16.9%), SPEN (16.9%), with 17.1 7.2 (mean standard error of the mean [SEM]) mutations/individual. TP53 mutations (p = 0.005707) were associated with a significantly worse prognosis, as determined by log-rank test. The hazard ratios for cases with this mutation was 2.6390 (95% CI, 1.2180–5.720, p = 0.0139) for TP53. Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic SDC. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.

  • Genetic mutations in recurrent and/or metastatic nasal carcinoma: A pathological comparison based on the Japanese national genomic profiling database

    by Hiromi Nagano, Satoshi Kiyama, Kyutoku Takayuki, Hayato Matsumoto, Masaru Yamashita

    Introduction: Comprehensive genome profiling (CGP) has been reimbursed under Japan’s national health insurance since 2019 for patients with advanced solid tumors, including head and neck cancers. Despite this, genomic insights into rare nasal carcinoma subtypes remain limited, hindering subtype-specific therapeutic strategies. Aim: To characterize the genetic mutational profiles of recurrent and/or metastatic nasal carcinoma across histological subtypes using data from the Japanese National Genomic Profiling Database. Materials and methods: Genomic data from 135 patients with nasal carcinoma were analyzed, including squamous cell carcinoma (SCC) (n = 48), neuroendocrine tumor (NET) (n = 52), adenocarcinoma (n = 20), and undifferentiated carcinoma (n = 15). All cases were registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center Japan, between June 2019 and May 2025. Mutations were identified via FoundationOne CDx next-generation sequencing. Survival analysis employed the log-rank test and Cox proportional hazards model. Results: TP53 and KMT2D were frequently mutated across all subtypes. In SCC, KMT2D (p = 0.03), EGFR (p = 6.4 × 10-), and RICTOR (p = 0.03) mutations correlated with poor prognosis. No significant differences were found among subtypes in mutation count or tumor mutational burden (TMB). Discussion: Shared and distinct mutational patterns were observed, with prognostic relevance in SCC. These findings underscore the importance of genomic stratification in rare nasal carcinomas. Conclusions: CGP reveals key genetic drivers in nasal carcinoma, supporting its role in precision oncology and informing future subtype-specific therapeutic approaches.


  • Genetic mutations in recurrent and/or metastatic squamous cell carcinoma of unknown primary – an analysis of the Japanese national genomic profiling database

    by Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Hayato Matsumoto, Masaru Yamashita

    Introduction: Although genetic mutations have been reported in squamous cell carcinoma of unknown primary (SCCUP), no scientifically validated targeted therapies are currently available. Moreover, cancer genomic profiling tests remain underutilized in clinical practice. These issues highlight the urgent need to elucidate the genomic landscape of SCCUP and its potential therapeutic relevance.Aim: This study aimed to characterize the mutational profile of recurrent and/or metastatic SCCUP.Materials and methods: Data were analyzed for 170 consecutive patients with SCCUP registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and August 2025. Genetic mutations were determined by next-generation sequencing. The survival of patients was determined by the log-rank test and a Cox proportional hazards model.Results: The top 10 mutations in SCCUP were TP53 (57.6%), CDKN2A (37.0%), PIK3CA (32.9%), KMT2D (27.6%), CDKN2B (20.6%), NOTCH3 (20.6%), BRAC2 (20.0%), PTEN (16.5%), NOTCH1 (15.9%), and RICTOR (15.9%), with 20.2 10.1 (mean SEM) mutations/ individual. Mutation in BRCA2 (p = 0.0347) was associated with a significantly worse prognosis, as determined by the log-rank test. The hazard ratios for cases with this mutation was 2.3450 (95% CI, 1.2220–4.499, p = 0.01037) for BRCA2.Conclusions: This study delineated the mutational spectrum of recurrent and/or metastatic SCCUP. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.